Previous close | 383.05 |
Open | 383.05 |
Bid | 386.95 x 0 |
Ask | 387.80 x 0 |
Day's range | 383.05 - 383.05 |
52-week range | 235.10 - 383.05 |
Volume | |
Avg. volume | 4 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
FDA review of historic data shows patients who received robotic prostatectomies have overall cancer survival rates on par with open surgerySUNNYVALE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced today that the U.S. Food and Drug Administration (FDA) cleared a labeling revision for da Vinci X and Xi specific to radical prostatectomy. This clearance was based on real-w
Lewis Chew elected to Intuitive’s BoardAlan Levy, PhD and Don Kania, PhD to retire from Board SUNNYVALE, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Intuitive (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced today that Lewis Chew, former chief financial officer at Dolby Labs, Inc., has been elected to the Company’s Board of Directors, effective April 25. “Lewis brings decades of experience across global organizations, tec
SUNNYVALE, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended March 31, 2024. Q1 Highlights Worldwide da Vinci procedures grew approximately 16% compared with the first quarter of 2023.The Company placed 313 da Vinci surgical systems, compared with 312 in the first quarter of 2023.The Company grew its da Vinci